obesity drug news today glp-1 oct 27 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Pentagon Drops Coverage of GLP-1

Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower ...

The GLP-1 boom is making people desperate to get the pricey weight-loss drugs

Leah Joseph at Josephcarerx Clarifies the Key Differences Between GLP-1 and Ozempic to Help You Make Informed Health Decisions.

The Ozempic vision loss lawsuit involves claims that semaglutide medications, including Ozempic, Wegovy, and Rybelsus, may be associated with non-arteritic...

For best results, we recommend 3-6 months of consistent daily use

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists